AGC Inc. Revised consolidated earnings guidance for fiscal year ending December 31, 2025. For the period, the company revised net sales of JPY 2,050,000 million compared to previous forecast of JPY 2,150,000 million. Operating profit of JPY 120,000 million compared to previous forecast of JPY 150,000 million.
Profit for the period of JPY 68,000 million compared to previous forecast of JPY 98,000 million. Profit for the period attributable to owners of the parent of JPY 57,000 million compared to previous forecast of JPY 80,000 million. Basic earnings per share of JPY 268.84 compared to previous forecast of JPY 377.43.
Net sales and operating profit are expected to be lower than the forecast due to several factors: the significant shortfall in sales volume caused by a production issue in the biopharmaceuticals CDMO business in the Life Science segment; the lower sales price of PVC in the Chemicals segment; and the shortfall in sales volume of semiconductor-related products in the Electronics segment. Profit before tax, profit for the period, and profit for the period attributable to owners of the parent are also expected to be lower than forecast due to the aforementioned factors and the recognition of impairment losses resulting from the decision to proceed with structural reforms regarding the Boulder site and the Longmont site in Colorado, USA, as part of the biopharmaceuticals CDMO business.
